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Purpose: To determine the levels of bone and cartilage
turnover markers in men with ankylosing spondylitis (AS) and
to investigate their associations with disease activity, bone
mineral density, and radiographic damage of the spine.
Patients and Methods: This cross-sectional study enrolled 35
men with newly diagnosed AS. The bone mineral densities
(BMD) of their lumbar spines and proximal femurs, Bath AS
Disease Activity Index (BASDAI), and Bath AS Radiographic
Index (BASRI) were evaluated. Urinary C-terminal telopeptide
fragments of type I collagen (CTX-I) and type II collagen
(CTX-II) levels were determined by enzyme-linked immu-
nosorbent assay, and serum levels of bone-specific alkaline
phosphatase (BALP) and osteocalcin were determined by an
enzyme immunoassay. Levels of biochemical markers were
compared with those of 70 age-matched healthy men. Results:
Patients with AS had significantly higher mean urinary CTX-I
and CTX-II levels than control subjects (p < 0.05). Elevated
urinary CTX-I levels correlated well with BASDAI, femoral
BMD, and femoral T score (p < 0.05), and elevated urinary
CTX-II levels correlated well with spinal BASRI (p < 0.05) in
patients with AS. Mean serum BALP and osteocalcin levels
did not differ between patients and controls and did not show
any significant correlations with BMD, BASDAI, or BASRI
in men with AS. Conclusions: Elevated CTX-I reflects disease
activity and loss of femoral BMD while elevated CTX-II
levels correlate well with radiographic damage of the spine,
suggesting the usefulness of these markers for monitoring
disease activity, loss of BMD, and radiographic damage in
men with AS.
Key Words: Ankylosing spondylitis, bone mineral density, C-
terminal telopeptide fragments of type I collagen, C-terminal
telopeptide fragments of type II collagen, radiographic damage
INTRODUCTION
Enthesitis and syndesmophytosis are pathological
hallmarks of AS. Progressive stiffening of the
spine often results from new bone formation
induced by chronic inflammation in patients with
AS. In an apparent contradiction, vertebral osteo-
porosis is also commonly seen in cases of AS.
1,2
Bone loss predominates at the spine and femurs,
and vertebral fractures constitute a non- negligible
cause of morbidity. However, it is not certain
which subsets of patients with AS are susceptible
to the progression of new bone formation or
osteoporosis, and few laboratory markers have
proven to reliably indicate either disease activity
or loss of BMD in patients with AS.
3
Although syndesmophytosis represents increased
new bone formation in patients with AS, previous
reports show that the majority of patients with
advanced AS have decreased BMD.
4-6 The reason
for this discrepancy is not clear, nevertheless, it
has been suggested that the bone quality of
patients with AS may be influenced by various
confounders, such as the degree of inflammation,
and that bone growth and bone loss occur in
parallel. Besides the coexistence of both new bone
formation and bone resorption in patients with
AS, the pathology of this disease differs from that
of other articular disorders in that it is charac-
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terized by a greater tendency for involvement of
cartilaginous joints, including intervertebral discs
and manubrosternal joints.
7 In this regard, bio-
chemical markers that reflect bone and cartilage
turnover may be useful tools in monitoring
disease activity, osteoporosis, and radiographic
damage in patients with AS as well as in
identifying the subset of patients at particular risk
for serious morbidities associated with the disease.
Assays for the proteins produced by osteoblasts,
such as BALP and osteocalcin, have commonly
been used to assess the degree of bone formation.
8
In addition, measurement of CTX-I is one of the
most valuable assessments of osteoclastic activity,
9
whereas urinary CTX-II specifically reflect cartilage
degradation.
10 Previous studies have shown that
the levels of these bone and cartilage turnover
markers can be used to monitor changes of BMD
and predict the progression of joint damage in
several articular diseases.
11-14 The value of tracking
bone formation and resorption markers in patients
with AS is well recognized, and several previous
studies have established that increased bone
degradation markers are associated with increased
disease activity and loss of BMD in patients with
AS.
15-18 The association between bone degradation
markers and radiographic damage of the spine
has not clearly been elucidated, however, the role
of cartilage degradation markers has not yet been
reported in patients with AS.
To evaluate the potential uses of bone and
cartilage turnover markers in understanding
disease pathogenesis and in monitoring the
morbidities associated with AS, we determined
the levels of these markers in patients with AS
and investigated their association with disease




This cross-sectional study included 35 men with
newly diagnosed AS (mean age, 28.8 - 8.6 years;
range, 18 - 37 years) who visited the Division of
Rheumatology at Severance Hospital, Yonsei
University Medical Center, between January 2003
and January 2004. All patients fulfilled the
modified New York criteria for AS,
19 and the
mean disease duration from symptom onset to
study enrollment was 20.1 - 15.0 months (range,
6.0 - 61.0 months). Patients who had been treated
with calcium, vitamin D, bisphosphonate, gluco-
corticoids, anticonvulsants, or anticoagulants prior
to study enrollment, and those with a medical
illness or spinal disease other than AS, such as a
herniated spinal disc, were excluded. Patients
with peripheral arthritis were also excluded
because the presence of peripheral arthritis can
influence the levels of bone and cartilage turnover
markers. Seventy age-matched healthy men (mean
age, 29.2 - 8.8 years; range, 19.0 - 37.0 years) were
enrolled as control subjects. This study was
approved by the ethics committee of our institute,
and signed informed consent was obtained from
all study participants.
Clinical assessments
BMD of men with AS was measured at the
posteroanterior lumbar spine (L1-4) and femoral
neck using dual energy X-ray absorptiometry
(DXA). Results are expressed as BMD in g/cm
2
and T scores using a Hologic QR4500 densi-
tometer. T score was defined as the standard
deviation by which a patient’s BMD differed
from the mean BMD of normal Korean young
controls, provided by the Korean branch of the
densitometer’s manufacturer. Validated clinical
criteria from the AS assessment working group
were also measured, including BASDAI for disease
activity




Biochemical assays were performed on fasting
morning blood samples and fasting second morning
void urine samples obtained concurrently with
assessments of clinical parameters. Serum BALP
and osteocalcin levels were determined using
enzyme immunoassay (EIA, Metra Biosystems,
Mountain View, CA, USA), according to the
manufacturer's protocol. Both intra- and inter-
assay coefficients of variation for tests were lower
than 7%.Min-Chan Park, et al.
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Urinary CTX-I levels were measured by urine
CrossLaps enzyme-linked immunosorbent assay
(ELISA; Nordic Bioscience Diagnostics, Herlev,
Denmark), which uses a polyclonal rabbit antiserum
containing an antibody against a sequence in the
C-terminal telopeptide 1 chain of human type I α
collagen.
9 Both intra- and inter-assay coefficients
of variation were both than 9%. Urinary CTX-II
levels were determined by urine CartiLap ELISA
(Nordic Bioscience Diagnostics) based on a
monoclonal antibody raised against the EKGPDP
sequence of the human C-terminal telopeptide
fragment of type II collagen,
8 with intra- and
inter-assay coefficients of variation below 6% and
8%, respectively.
ESR was measured by a modified Westergren
method (reference range < 15 mm/hr in men and
< 20 mm/hr in women), and CRP level was deter-
mined by immunonephelometry (reference range
< 0.8 mg/dL in all subjects; BN-II nephelometer,
Dade-Behring, Marburg, Germany).
Statistical analysis
All data are expressed as mean ± SD, and data
from biochemical assays represent duplicate
measurements. Results were analyzed using
Mann-Whitney U test, and correlations were
evaluated using Pearson's correlation test. P
values less than 0.05 were considered statistically
significant.
RESULTS
Comparison between patients and controls
The demographic, clinical, and laboratory
characteristics of patients with AS and of control
subjects are summarized in Table 1. Mean age
of patients with AS was not different from that
of controls. Mean ESR and CRP levels of
patients with AS were significantly higher than
those of the controls as were urinary CTX-I (p =
0.014) and CTX-II (p < 0.001) levels. The differ-
ences between patients with AS and controls for
BALP and osteocalcin were not statistically
significant.
Correlations between biochemical and clinical
parameters
Table 2 shows correlations between biochemical
and clinical parameters in patients with AS. The
age and disease duration were not significantly
related to any of the clinical or biochemical
parameters, although CRP levels correlated well
with BASDAI (r = 0.612, p < 0.001) while ESR did
not. Among the clinical parameters, significant
inverse correlations were found between BASDAI
and femoral neck BMD (r = - 0.493, p = 0.003) and
between BASDAI and femoral neck T scores (r =
- 0.568, p < 0.001) in patients with AS.
Serum BALP and osteocalcin levels did not
correlate with any of the clinical or laboratory
parameters. Urinary CTX-I levels showed signi-
ficantly inverse correlations with femoral neck
BMD (r = - 0.414, p = 0.030) and femoral neck T
scores (r = - 0.399, p = 0.037), but not with spinal
BMD or T score. There were significantly positive
correlations between urinary CTX-I levels and
BASDAI (r = 0.445, p = 0.016) as well as between
urinary CTX-I and CRP levels (r = 0.491, p = 0.006).
A significantly positive correlation was also found
between urinary CTX-II levels and spinal BASRI
(r = 0.472, p = 0.010).
DISCUSSION
In the present study, an elevated urinary CTX-I
level, a marker for bone resorption, was found to
reflects increased disease activity and decreased
BMD in men with AS. Although this study enrolled
young men (mean 28.8 years) so as to exclude
confounding factors of osteoporosis, such as age,
sex, and menopause, both BMD and T scores
measured in men with AS in this study were
relatively lower than in normal Korean young
men. In addition, a strong correlation was found
between disease activity and loss of femoral neck
BMD. Previous studies have demonstrated that
patients with AS have normal bone formation
marker levels and increased bone resorption
markers, and that bone resorption markers reflect
disease activity and the development of osteo-
porosis in patients with AS.
15-18 In agreement with
these previous findings, our patients with AS hadTable 2. Correlations between Biochemical Parameters and Clinical Parameters in Patients with Ankylosing Spondylitis









Serum BALP (IU/L) 0.141 0.127 0.190 0.211 - 0.266 - 0.227 - 0.012 - 0.088
Serum osteocalcin (ng/mL) 0.189 0.211 0.005 - 0.196 - 0.037 - 0.102 - 0.270 - 0.244
Urine CTX-I ( g/mmol Cr) μ 0.253 0.491* 0.445* 0.186 - 0.300 - 0.274 - 0.414* - 0.399*
Urine CTX-II ( g/mmol Cr) μ 0.109 0.099 0.271 0.472* 0.008 0.115 0.197 0.317
BALP, bone specific alkaline phosphatase; CTX, C-terminal telopeptide fragments; Cr, creatinine; BASDAI, Bath ankylosing
spondylitis disease activity index; BASRI, Bath AS radiographic index; BMD, bone mineral density.
Results are shown as the correlation coefficients, calculated using Pearson’s correlation test.
*p value < 0.05 by Pearson’s correlation test.
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Table 1. Main Characteristics of Patients with Ankylosing Spondylitis and Controls
Characteristics AS patients (n = 35) Controls (n = 70) p value
Age (yrs) 28.8 ± 8.6 29.2 ± 8.8 0.821
Disease duration (months) 20.1 ± 15.0 - -
DXA findings
Lumbar vertebrae 1 - 4
BMD (g/cm
2) 1.01 ± 0.19 - -
T score - 0.37 ± 0.60 - -
Femur neck
BMD (g/cm
2) 0.81 ± 0.12 - -
T score - 1.11 ± 0.54 - -
BASDAI 7.0 ± 4.6 - -
BASRI-spine 3.2 ± 2.1 - -
Biomarker levels
Serum BALP (IU/L) 19.1 ± 5.3 16.0 ± 6.0 0.101
Serum osteocalcin (ng/mL) 11.7 ± 3.3 8.2 ± 3.9 0.060
Urine CTX-I ( g/mmol Cr) μ 279.9 ± 84.4 152.5 ± 91.9 0.014
Urine CTX-II level ( g/mmol Cr) μ 472.3 ± 159.0 259.1 ± 125.4 0.001
Acute phase reactants
ESR, mm/hour 37.7 ± 20.1 9.7 ± 4.0 0.001
CRP, mg/dL 1.1 ± 0.8 0.3 ± 0.1 0.003
DXA, dual energy X-ray absorptiometry; BMD, bone mineral density; BASDAI, Bath ankylosing spondylitis disease activity index;
BASRI, Bath AS radiographic index; BALP, bone specific alkaline phosphatase; CTX, C-terminal telopeptide fragments; Cr,
creatinine; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.Min-Chan Park, et al.
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normal bone formation markers and an increased
bone resorption marker, and the increased bone
resorption marker showed significantly positive
correlation with disease activity and significantly
inverse correlation with BMD in men with AS.
These data support the theory that patients with
AS have unbalanced bone turnover, and that
inflammatory activity can alter bone metabolism
and lead to osteoporosis.
15-18
In our study, urinary CTX-I levels were signi-
ficantly correlated only with loss of femoral neck
BMD but not with loss of spinal BMD. Previously,
Bronson et al. showed that BMD was significantly
lower at the femur neck but not the postero-
anterior lumbar spine in patients with AS than in
control subjects,
22 and they suggested that
ankylosis of the posterior elements of the spine
might contribute to the false elevation of postero-
anterior lumbar BMD measured by DXA. Baek et
al. also showed that the progression of bone loss
may be reflected more reliably at proximal femur
sites than at the lumbar spine.
23 Thus, the
possibility exists that syndesmophytosis, a process
of new bone formation, caused an over-estimation
of BMD in our study since it was measured at the
posteroanterior lumbar spine.
The role of CTX-II measurement has been em-
phasized in several articular diseases other than
AS. Our data demonstrate that urinary CTX-II
levels, which specifically indicate degradation of
cartilage, are also increased and related to radio-
graphic damage of the spine in patients with AS.
Significant associations of urinary CTX-II level
with long-term progression of joint destruction in
rheumatoid arthritis and with joint damage in
severe osteoarthritis have been reported.
9-11
However, the role of this cartilage degradation
marker has not been determined in patients with
AS, and our study is the first to report a signi-
ficant correlation between increased urinary CTX-
II levels and radiographic damage of the spine in
patients with AS.
It is interesting to note that only the cartilage
degradation marker showed a significant associa-
tion with the parameter reflecting spinal damage
in our patients. Radiographic damage of the spine,
as assessed in this study by BASRI-spine, reflects
syndesmophytosis,
21 and syndesmophytosis repre-
sents pathological new bone formation in the
spine. But bone formation markers were not found
to be associated with BASRI-spine, and their
serum levels in patients with AS were not
different from those in controls. The significant
association between a cartilage degradation marker
and radiographic damage of the spine observed in
this study suggests a role for cartilage in the
pathogenesis of syndesmophytosis in patients
with AS.
The pathogenic mechanisms responsible for the
spinal damage and ankylosis observed in patients
with AS are unknown. Although enthesitis is a
distinctive feature of AS, its relevance to the
pathogenesis of synovitis and its significance to
the pathogenesis of disease at various other
articular and extra-articular sites typically affected
by AS, such as the sacroiliac joint, hip joint, and
anterior uvea, are questionable. The disparate
clinical, pathological, radiological, and immunolo-
gical data in AS are more consistent with an
alternative hypothesis of primary autoimmunity
to cartilage and, in particular, to fibrocartilage.
7 A
peculiar predilection at fibrocartilaginous sites,
including the intervertebral discs, manubrio-
sternal joints, and symphysis pubis, is widely
appreciated in AS.
24,25 Proteoglycans present in
cartilage and fibrocartilage have been shown to be
involved in the immune response in spondyloar-
thritides,
26,27 and a histopathological study of
sacroiliitis showed that a proliferative process of
cartilage metaplasia and endochondral ossifica-
tion, fibrosis, and formation of woven bone led to
ankylosis.
28 These observations suggest that car-
tilage, particularly fibrocartilage, may be another
target of inflammation in AS and may be involved
in syndesmophytosis. In this regard, the signi-
ficant association between a cartilage degradation
marker and spinal damage observed in this study
supports the role of cartilage and its degradation
in the pathogenesis of AS. Furthermore, our
finding suggests that measurement of CTX-II
levels can be useful in monitoring spinal damage
in patients with AS. Further investigations enrolling
a larger number of patients are needed to confirm
the relationship found in this study and to gain
better understanding of the role of cartilage in the
pathogenesis of AS, particularly in the process of
syndesmophytosis.
In summary, urinary CTX-I and CTX-II wereBone and Cartilage Turnover Markers in AS
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elevated in men with AS and correlated well with
disease activity, osteoporosis of the femur neck,
and radiographic damage of the spine. Our
findings suggest that these markers can be used
to monitor disease activity, loss of BMD, or
radiographic damage of the spine as well as to
identify patients with AS who are at particular
risk for serious complications and would thus
benefit from more aggressive treatment early in
the disease.
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